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Abstract 
Hepatitis B is a virus that mostly affects the liver, it could be asymptomatic and if left 
untreated or undetected, could lead to liver cancer, cirrhosis or even death. When Hepatitis B 
virus enters the body, it could be detected as early as 30 days post exposure and if it persists, 
may develop into a chronic condition. Chronic hepatitis B is the persistence of hepatitis B 
surface antigen for six months or more.  It is a global health problem in which an estimated 2 
billion people worldwide are infected and with about 2.2 million people infected in the United 
States. This manuscript discusses the importance of screening for chronic hepatitis B virus in 
eligible individuals so as to identify infected and/or susceptible individuals. It also discusses 
hepatitis B vaccination as the best way to prevent the virus, the geographic distribution of 
chronic hepatitis B virus, and the eligibility criteria for screening following the recommendations 
of the Centers of Disease Control and Prevention (CDC) and United States Preventive Services 
Task Force USPSTF).  
 
Keywords: hepatitis, chronic hepatitis b, hepatitis b screening, hepatitis b vaccination, and 
hepatitis b prevention.  
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Introduction 
Hepatitis B virus is a life-threatening virus that affects the liver, and it is known to be the 
oldest virus ever found in humans [1]. Hepatitis B is a blood borne pathogen transmitted via 
blood contact, body fluid or sexual contact. It is spread when an uninfected person comes in 
contact with the body fluids (such as blood, saliva, vaginal and seminal fluids) of someone who 
is infected. This could happen through sharing of needles, sexual contact, or from mother to baby 
at birth [2]. Hepatitis B is found worldwide but regions differ in endemicity, it is worthwhile to 
note that most of the world’s population lives in areas with high hepatitis B endemicity [3]. 
Hepatitis B virus can exist in both acute and chronic phases and chronic hepatitis B can lead to 
cirrhosis or liver cancer, hence the Centers for Disease Control and Prevention (CDC) has set 
forth recommendations to screen eligible patients [4, 2].  
The CDC reports that about 2.2 million people in the United States are infected with 
chronic hepatitis B and in 2016, hepatitis B was listed in 1715 death certificates as a cause of 
death [5, 6]. Chronic hepatitis B is often asymptomatic and when symptoms eventually present, 
they could signal a late stage of liver cirrhosis, liver cancer or even death [5]. Hence, the World 
Health Organization (WHO) and the CDC have set forth recommendations to screen for chronic 
hepatitis B virus [7]. Individuals with chronic hepatitis B can still transmit the virus even when 
they do not have symptoms themselves [7].  Oftentimes, symptoms of chronic hepatitis B present 
as a vague feeling of illness which can include fatigue, poor appetite, and a discomfort in the 
upper abdomen. The first specific symptoms of chronic liver disease can include an enlarged 
spleen, redness of the palm and ascites [8]. Chronic hepatitis B virus which can lead to 
hepatocellular carcinoma is a rising cause of mortality and significant health burden [9]. About 
15% to 40% of individuals diagnosed with chronic hepatitis B virus progress to cirrhosis, liver 
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failure and liver cancer if untreated [30]. Early screening will identify susceptible or infected 
individuals, and as a result, the former can be vaccinated while the latter can be treated in order 
to decrease or slow down the progression of the disease [7]. 
Chronic hepatitis B virus infection, defined as hepatitis B surface antigen (HBsAg) 
positivity for at least 6 months, is a major cause of morbidity and mortality worldwide [10]. 
Wilkins, Sams, and Carpenter (2019) further defined chronic hepatitis B as the persistence of 
hepatitis B surface antigen for more than six months. They state that although individuals who 
have chronic hepatitis B are at risk of hepatocellular carcinoma and cirrhosis, morbidity and 
mortality are reduced with adequate and timely treatment [11].  
 
Geographic Distribution of Chronic Hepatitis B Virus 
 
Hepatitis B virus is found worldwide but differs in endemicity (See appendix A and B). 
According to the World Health Organization, most of the world’s population lives in countries 
where the prevalence of hepatitis B surface antigen (HBsAg) in the general population is high 
(≥8%) or intermediate (27%). The prevalence of hepatitis B virus remains low in certain areas 
of North America, Northern and Western Europe, the southern Cone of South America, Australia 
and New Zealand [12]. The CDC also supports the WHO’s data, which found that about 45% of 
the world’s population lives in areas of high hepatitis B endemicity where the prevalence is 8 
and a lifetime risk of acquiring it is >60%. Another 43% live in areas of intermediate endemicity 
with a prevalence of 2-7% where the lifetime risk of acquiring it is 20-60%, and only about 12% 
of the world’s population lives in areas of low endemicity where the prevalence is <2% with a 
lifetime risk of <20% [10].  
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CDC’s Recommendations for Screening  
 
The CDC has the following recommendations of persons or groups eligible for screening 
for chronic hepatitis B virus (see appendix c). This includes persons born in geographic regions 
with HBsAg prevalence of ≥2%, US born persons not vaccinated as infants whose parents were 
born in geographic regions with HBsAg prevalence of ≥8%, injection-drug users, men who have 
sex with men, persons with elevated ALT/AST of unknown etiology, persons with selected 
medical conditions who require immunosuppressive therapy, pregnant women, infants born to 
HBsAg-positive mothers, household contacts and sex partners of HBV-infected persons, persons 
who are the source of blood or body fluids resulting in exposures that might warrant post 
exposure prophylaxis (e.g., needle stick injury to a health care worker) and persons infected with 
HIV [13]. The United States Preventive Services and Task Force (USPSTF) also recommends 
chronic hepatitis B screening in high risk individuals. They defined high risk as those from 
countries with a high prevalence of HBV infection, HIV-positive persons, intravenous drug 
users, men who have sex with men, and household contacts of persons with HBV infection [14]. 
The recommendation, according to USPSTF, is to screen for chronic hepatitis B using the 
HBsAg [15]. 
Prevention and Vaccination 
 
 The CDC recommends screening for chronic hepatitis B and the best way to prevent it is  
 
by getting vaccinated [16]. The American Association for the Study of Liver Diseases were of 
the view that Hepatitis B screening should be done using both the HBsAg and Anti-Hbs, 
individuals who are Anti-Hbs negative should be vaccinated [17]. The American College of 
Physicians and CDC recommends hepatitis B screening for adults at high risk, they also 
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recommend HBV vaccination for people who request it and for unvaccinated adults including 
pregnant women [18].  
 A study published in the New England Journal of Medicine noted that chronic hepatitis  
has become a global public health challenge and they recommend that testing and treatment  
 
of chronic HBV remains the primary means of reducing HBV related death by 65% [19]. The 
CDC reported that hepatitis B kills about 2,000 people in the U.S. yearly, and the hepatitis B 
vaccine can prevent hepatitis B and its related complications such as liver cancer and cirrhosis 
[20]. Hepatitis B could be preventable with the administration of the hepatitis B vaccination. The 
WHO has identified hepatitis as a global problem and has called for its elimination by 2030, they 
defined elimination as a 90% reduction in incidence rate and a 65% reduction in number of 
deaths [19]. Hepatitis B vaccine is made from parts of the virus and it is important to note that it 
cannot cause hepatitis B infection. It is usually given as 2, 3, or 4 series over one to six months 
period [20]. Hence, the vaccine is recommended for unvaccinated adults at risk for hepatitis B 
virus, this includes but is not limited to people whose sex partners have hepatitis B, men who 
have sex with men, healthcare and public safety workers at risk for exposure to body fluids, and 
people with chronic liver disease, HIV, kidney disease and diabetes [20].  
Pre-exposure and post-exposure prophylaxis 
  
 Preventing hepatitis B virus prior to exposure by immunization remains the best way to 
prevent HBV infection, hence vaccination of newborns is recommended in most countries [21]. 
Pre-exposure vaccination should be offered to individuals who are not immune, healthcare 
workers, men who have sex with men, HIV positive patients and hepatitis C infected individuals 
[21]. Although prevention is more effective than therapy, post-exposure prophylaxis with 
hepatitis B vaccine and/or hepatitis B immune globulin (HBIG) can reduce transmission of HBV 
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by 70-90% after an exposure when administered within 12-24 hours of an exposure [22,23].  
Post-exposure prophylaxis is indicated for individuals without previously documented HBV 
immunity who are exposed to blood/body fluids from a HBsAg positive or unknown HBV status 
source and should not be given to individuals with a known history of recovery from HBV 
infection [23].  
Vaccine Formulations 
 
 Hepatitis B immunization can either be passive or active [22], passive immunization 
provides temporary immunity using HBIG while active immunization provides long-term 
immunity [22]. Passive immunization is not routinely recommended for healthy adults because it 
is typically used for immunocompromised patients [24]. There are different classes of hepatitis B 
vaccines: single antigen vaccines (yeast derived, mammalian cell derived, and plasma derived), 
and combination vaccines [25]. Plasma derived vaccines were the first vaccines but have been 
replaced over the years by yeast and mammalian cells using recombinant DNA technology [26]. 
Recombinant hepatitis B vaccines-conventional (Recombivax HB and Engerix B) are typically 
given in three doses over a six-month period [25,26]; and the recombinant hepatitis B vaccine 
(CpG-adjuvanted sold under the name Heplisav-B) is used in adults 18 years [27]. Hepatitis B 
vaccine can also be combined with another vaccine such as hepatitis A vaccine, (Twinrix-
combined HepB-HepA vaccine), this is ideal and beneficial because it increases compliance and 
reduces the number of injections [25]. Hepatitis B vaccine is generally safe and effective in 
protecting against HBV, protective antibody levels achieved in 95% of those vaccinated [26]. A 
booster dose is recommended if antibody levels falls <10 milli international units/mL for 
individuals who are immunocompromised or on dialysis [25]. 
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Contraindications, Precautions and Adverse Events 
  
 According to Hibberd (2019), administering a live vaccination to an individual who is 
immunocompromised is contraindicated. Vaccination should be avoided only if a true 
contraindication exists such as previous anaphylactic reaction to a specific vaccine, history of 
anaphylaxis to eggs and/or neomycin. In the event of an adverse reaction, it should be reported to 
the United States Department of Health and Human Services [24]. 
Summary  
 
Chronic hepatitis B virus has become a major global threat, one that leads to liver  
 
cirrhosis and hepatocellular carcinoma and claims about 1 million lives worldwide annually [28]. 
It is imperative to note that the disease burden of chronic hepatitis B is high in the Asian Pacific 
region, hence the United Nations Sustainable Development Goals for 2030 include combating 
hepatitis [29]. About 15% to 40% of people with chronic hepatitis B progress to cirrhosis if not 
treated [30]. As part of the discussion in this manuscript, the recommendation therefore, is to 
screen for chronic hepatitis B virus using the HbsAg blood test, in order to identify individuals 
who are infected and treat them to prevent/reduce the progression of the disease. And, it is also 
critically important to screen using the Anti-Hbs in order to identify susceptible individuals and 
vaccinate them to further prevent exposure to the virus. The USPSTF has enough evidence that 
hepatitis B vaccination is effective in decreasing the chances of acquiring the virus [14]. Hence, 
the need for healthcare providers to screen eligible patients, vaccinate susceptible individuals and 
treat those with the virus in order to slow down the progression of the disease.  
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Appendix A: Geographic Distribution of Chronic HBV Infection 
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Appendix B: Geographic Regions with a Prevalence of Hepatitis B Surface Antigen ≥2% 
(USPSTF 2014) 
Region Countries 
Africa All 
Asia All 
Australia and South Pacific All except Australia and New Zealand 
Middle East All except Cyprus and Israel  
Eastern Europe  Malta, Spain, and indigenous populations in 
Greenland 
North America Alaska natives and indigenous populations in 
northern Canada  
Mexico and Central America Guatemala and Honduras 
South America Ecuador, Guyana, Suriname, Venezuela, and 
Amazonian areas of Bolivia, Brazil, 
Colombia, and Peru 
Caribbean  Antigua and Barbuda, Dominica, Grenada, 
Haiti, Jamaica, St. Kitts and Nevis, St. Lucia, 
and Turks and Caicos Islands 
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Appendix C: CDC’s Recommendation for Routine Testing and Follow-up for Chronic 
Hepatitis B Virus Infection (CDC, 2008) 
Population Testing  Vaccination/Follw-up 
Persons born in regions of high 
and intermediate HBV endemicity 
(HBsAg prevalence 2%) 
Test for HBsAg, regardless of 
vaccination status in their 
country of origin, including 
immigrants, refugees, asylum 
seekers and internationally 
adopted children 
If HBsAg-positive, refer for medical 
management. If negative, assess for 
on-going risk for hepatitis B and 
vaccinate if indicated 
US born persons not vaccinated as 
infants whose parents were born 
in regions with high HBV 
endemicity (8%) 
Test for HBsAg regardless of 
maternal HBsAg status if not 
vaccinated as infants in the 
United States 
If HBsAg-positive, refer for medical 
management. If negative, assess for 
on-going risk for hepatitis B and 
vaccinate if indicated 
Injection-drug users  Test for HBsAg, as well as 
anti-HBc or anti-HBs to 
identify susceptible persons 
1
st
 vaccine dose should be given 
same visit as testing. Susceptible 
persons should complete a 3-dose 
hepatitis B vaccine series 
Men who have sex with men  Test for HBsAg, as well as 
anti-HBc or anti-HBs to 
identify susceptible persons 
1
st
 vaccine dose should be given 
same visit as testing. Susceptible 
persons should complete a 3-dose 
hepatitis B vaccine series 
Persons needing 
immunosuppressive therapy, 
including chemotherapy, 
immunosuppression related to 
organ transplantation, and 
immunosuppression for 
rheumatologic or 
gastroenterologic disorders 
Test for all markers of HBV 
infection (HBsAg, anti-HBc, 
and anti-HBs)  
Treat persons who are HBsAg-
positive. Monitor closely persons 
who are anti-HBc positive for signs 
of liver disease 
Persons with elevated ALT/AST 
of unknown etiology 
Test for HBsAg along with 
other appropriate medical 
evaluation 
Follow up as indicated 
Donors of blood, plasma, organs, 
tissues, or semen  
Test for HBsAg, anti-HBc, and 
HBV-DNA as required 
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Hemodialysis patients Test for all markers of HBV 
infection (HBsAg, anti-HBc, 
and anti-HBs) 
Vaccinate against hepatitis B and 
revaccinate when serum anti-HBs 
titer falls below 10mIU/m 
All pregnant women Test for HBsAg during each 
pregnancy, preferably in the 1
st
 
trimester. 
Test at the time of admission 
for delivery if prenatal HBsAg 
test result is not available of if 
mother was at risk for infection 
during pregnancy 
If HBsAg positive, refer for medical 
management. To prevent perinatal 
transmission, infants of HBsAg-
positive mothers and unknown 
HBsAg status mothers should receive 
vaccination and post-exposure 
immunoprophylaxis in accordance 
with recommendations and within 12 
hours of delivery 
Infants born to HBsAg positive 
mothers 
Test for HBsAg and anti-HBs 
1-2 months after completion of 
at least 3 doses of a licensed 
hepatitis B vaccine series (ie., 
at age 9-18 months, generally at 
the next well-child visit to 
assess effectiveness of post-
exposure immunoprophylaxis). 
Testing should not be 
performed before age 9 months 
or within 1 month of the most 
recent vaccine dose 
Vaccination in accordance with 
recommendations  
Household, needle-sharing, or sex 
contacts of persons known to be 
HBsAg positive  
Test for HBsAg, as well as 
anti-HBc or anti-HBs to 
identify susceptible persons 
1
st
 vaccine dose should be given 
same visit as testing. Susceptible 
persons should complete a 3-dose 
hepatitis B vaccine series 
Persons who are the sources of 
blood or body fluids resulting in 
an exposure (e.g., needlestick, 
sexual assault) that might require 
post-exposure prophylaxis  
Test source for HBsAg Vaccinate healthcare and public 
safety workers with reasonably 
anticipated occupational exposures to 
blood or infectious body fluids. 
Provide post-exposure prophylaxis to 
exposed person if needed 
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HIV-positive persons  Test for HBsAg, as well as 
anti-HBc or anti-HBs to 
identify susceptible persons 
Vaccinate susceptible persons against 
hepatitis B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
